Lixte Biotechnology has signed an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke and NCI.
Exact Sciences Corp. has launched the Riskguard hereditary cancer test in the United States.
FDA approved Tagrisso (osimertinib) with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
FDA has accepted for Priority Review the biologics license application for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma that has progressed after at least three prior therapies.
The FDA Oncology Center of Excellence published its 2023 annual report.
Mainz Biomed N.V. and Praxisdienst formed a distribution partnership focused on the accessibility of Mainz Biomed’s flagship product, ColoAlert.
FDA has approved Onivyde (irinotecan liposome) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.
FDA has accepted the supplemental New Drug Application for Augtyro (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity.
MD Anderson Cancer Center and C-Biomex Ltd. have formed a strategic research collaboration agreement to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.
BioNTech SE, a next-generation immunotherapy company, and Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, have formed collaboration with the aim of advancing both companies’ autologous CAR T programs towards commercialization, pending regulatory authorizations.
